Secondary Outcome: All-Cause Mortality During follow-up, 748 patients (19.39%) in the GLP-1RA cohort and 1026 patients (26.59%) in the DPP-4i cohort died from any cause
His research primarily focuses on Drug Discovery and Development, Microbial Biotechnology, and Nanobiotechnology
Repeated, sustainable food changes that increase fermentable substrates in the colon and ensure regular protein at meals can change microbial fermentation patterns and modestly increase GLP-1 over weeks to months, leading to more consistent satiety for many people, though results vary by individual microbiome
Its more of a moderate and steady wins the race type of treatment, but with dedication and focus on overall wellness, the weight does release
JCI insight 4 , e129756 (2019)
Preclinical translation of the pharmacokinetics and pharmacodynamics of peptide therapeutics